{"prompt": "['accordance to the regulations of the Danish Data Protection Agency and all necessary approvals will be', 'obtained.', 'Serum high sensitive CRP is measured by routine method at Department of Clinical Biochemistry at', 'Herlev and Gentofte Hospital. Serum IL-6 is determined by ELISA (R&D) and YKL-40 is determined', 'by ELISA (Quidel) at Department of Medicine, Herlev and Gentofte Hospital. 92 cancer- and-', 'inflammatory protein profiles will be determined using the Olink array (www.Olink) at BioXpedia,', '\u00c2rhus. Serum GDF11 and GDF15 are determined by ELISA at Department of Sports Science and', 'Clinical Biomechanics, University of Southern Denmark. Data on the inflammatory biomarkers will be', 'used in analyses in the present study to investigate whether the exercise-based intervention affects the', 'inflammatory process, and to investigate the association between these biomarkers and clinical', 'outcomes.', '28', 'Protocol TOLCA - Breast Cancer Exercise v8 18.06.2018']['4.9 Time of data collection and tests', 'Data collection and tests will be performed at baseline, midway intervention (6 weeks), post-intervention', '(12 weeks), and follow-up (16 weeks). Schedule for data collection and tests are shown in Table 2.', 'Table 2 Data collection and tests.', 'Inclusion', 'Midway', 'Post-intervention', 'Follow-up', '(baseline)', '(6 weeks)', '(12 weeks)', '(16 weeks)', 'Informed consent, TOLCA', 'X', 'Informed consent (PRIMAB) 1', 'X', 'Clinical and medical data', 'X', 'X', 'X', 'X', 'Demographics', 'X', 'Health status (ECOG, CCI, CARG', 'X', 'toxicity risk score)', 'Feasibility measures', 'Recruitment rates', 'X', 'Retention', 'X', 'X', 'X', 'X', 'Adherence', 'X', 'X', 'Adverse events', 'X', 'X', 'Patients satisfaction', 'X', 'PROMs', 'PRPS', 'X', 'X', 'X', 'X', 'MDASI (measured once weekly)', 'X', 'X', 'X', 'X', 'EORTC QLQ-C30 & BR23', 'X', 'X', 'X', 'X', 'HADS', 'X', 'X', 'X', 'X', 'Physical tests', '30s-CST (primary outcome)', 'X', 'X', 'X', 'X', '6MWT', 'X', 'X', 'X', 'X', 'Gait speed, 6 m and 10m', 'X', 'X', 'X', 'X', 'Handgrip strength', 'X', 'X', 'X', 'X', 'Stair climb test', 'X', 'X', 'X', 'X', 'Physical activity', 'X', 'X', 'Biomarkers related to inflammation', 'X', 'X', 'X', 'Oncological treatment/toxicity', 'X', 'X', 'X', 'X', 'Body measures and composition', 'Weight, BMI', 'X', 'X', 'X', 'X', 'DXA scan', 'X', 'X', 'BI', 'X', 'X', '1 For patients with breast cancer who accept participation in the PRIMA B trial.', '4.10Analyses and statistics', '4.10.1 Sample size', 'No prior studies have investigated the minimal clinically important difference in the 30s-CST focusing', 'on cancer patients. However, according to a previous study focusing on patients with osteoarthritis, the', 'clinically important change in the 30s-CST was set at 2.6 repetitions (120). Based on results from prior', 'studies focusing on patients with advanced cancer, a standard deviation (SD) of around 3 has been', 'reported in the 30s-CST(121, 122). To be able to detect a difference of 2.6 repetitions in the between-', 'group difference in the 30s-CST at the 12-week assessment, and to obtain a type I error rate of 5% and', 'a', 'power of 90%, a sample size of 29 patients per study arm will be needed. To account for an expected', '29', 'Protocol TOLCA - Breast Cancer Exercise v8 18.06.2018']['dropout rate of ~40%, we decided to increase this number to a group size of 50. Thus, a total of 100', 'patients will be included in the study.', '4.10.2Analysis plan', '4.10.2.1 Quantitative data', 'Feasibility measures (acceptability, attrition, adherence, and adverse events) will be reported as numbers', 'and percentages. Reasons for declining participation will be analyzed descriptively with numbers and', 'percentages of patients declining for various reasons. Baseline characteristics will be calculated for all', 'patients included (total) and separately for intervention group and control group. For all quantitative', 'variables the median number and interquartile range (IQR) will be calculated, and for nominal variables', 'the number and percentage distribution will be calculated. Results from physical tests, blood test, body', 'measures, and questionnaires will be reported as means and standard deviations (SD) or as median and', 'IQR, as appropriate. Change over time in ordinal categorical values will be evaluated by a trend test', 'using logistic regression. In-group and between- group differences in continuous-level data, will be', 'performed using a repeated measurement analysis. Survival analyses will be conducted with Kaplan-', 'Meier method, competing risk analyses and Cox regression analyses. Using the Kaplan-Meier method,', 'cancer-specific and overall survival time will be assessed for the intervention group and the control', 'group, and comparison in survival between groups will be assessed using the log-rank test. To account', 'for competing risks (deaths from other causes than cancer), the cumulative incidence of cancer-specific', 'death will be assessed using competing risk analyses, and comparison between groups will be conducted', \"using Grey's test. Cox proportional hazards regression will be used to estimate the hazards (risk) of\", 'death, and cause specific Cox proportional hazards regression will be used to assess the risk of cancer-', 'related death. The significance level of all tests is set a p < 0.05, and analyses will be carried out in SAS', 'or R by statisticians in collaboration with the primary investigator.', '5 Ethical considerations', 'Study approval will be obtained by the Scientific Ethics Review Committee of the Capital Region of', 'Denmark and the Danish Data Protection Agency. The study will also be registered at ClinicalTrials.gov.', 'TOLCA - Breast Cancer Exercise will be carried out in accordance with the protocol, and according the', 'Helsinki Declaration. All personal data will be treated with confidentiality and security in accordance', 'with the Danish Personal Data Act.', 'All potential participants will be provided with full and adequate verbal and written information about', 'the project and will have the right to ask questions about the study. Each patient will be informed about', 'their personal rights when entering the study. It is emphasized that participation in the study is voluntary,', '30', 'Protocol TOLCA - Breast Cancer Exercise v8 18.06.2018']\n\n###\n\n", "completion": "END"}